Slone Partners Recruits Chief Business Officer for InterVenn Biosciences
December 4, 2020 – Over the past few months, numerous healthcare and life sciences organizations have turned to executive search firms to find new leaders. In the era of COVID-19, the sector has been a burgeoning area for executive search firms to ply their trade. Recently, life sciences-focused search firm Slone Partners placed John Leite as chief business officer at InterVenn Biosciences in South San Francisco, CA.
“John Leite is an experienced and highly accomplished business development and marketing specialist in the biotechnology and diagnostics sectors,” said Tara Kochis-Stach, president of Slone Partners. “He brings a keen strategic sensibility and an extremely successful track record to the InterVenn executive team,” she added. “We are thrilled to bring John on board at a very exciting time for our company,” said Aldo Carrascoso, CEO at InterVenn. “He and the rest of our global leadership team are poised to move us forward as we continue to make tremendous progress in the diagnosis and treatment of various diseases through the use of glycoproteomics.”
Over the past six years, Mr. Leite served as vice president of oncology, market development and product marketing for the oncology business unit at Illumina. Prior to joining Illumina, he was vice president of commercial strategy and market access for Genoptix Inc., where, from 2008 to 2014, he drove several functions including marketing and business development, building the portfolio of oncology diagnostic services. Mr. Leite began his career as a scientist for Invitrogen (now Thermo Fisher Scientific), before transitioning to the business team as a marketer overseeing product management of the proteomics portfolio.
In his role with InterVenn Biosciences, he will direct all business operations for the company as part of its global leadership team. “I’m thrilled and honored to join the executive leadership team at InterVenn,” Mr. Leite said. “I’m humbled but inspired by the task of driving glycoproteomics as a new diagnostic nomenclature to stratify patients, classify disease and spawn new medical innovation.”
Related: Slone Partners Finds CEO for Epic Sciences
InterVenn Biosciences utilizes a proprietary glycoproteomic biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification and disease progression.
New State Capital Partners Takes Equity Stake in Klein Hersh
New State Capital Partners, based in Larchmont, NY, has taken an equity investment stake in Horsham, PA-based Klein Hersh International, an executive search firm focused on the life sciences and healthcare industries.
New State was advised on the transaction by Morgan Lewis (legal), Duff & Phelps (financial), L.E.K. Consulting (industry), and Citizens Bank (M&A advisory). Financial terms of the transaction are not being disclosed.
According to recruiters specializing in the field, pharmaceutical, healthcare and biotech companies have been at the forefront of the COVID-19 response, bearing heavy responsibility – from drug trials and vaccine development to the production of personal protective equipment and ventilators. That work overload has created an unusual supply and demand curve for talent, across virtually every function, and that is creating a big upswing in business for search firms focused on the sector. In demand are telehealth specialists, logistics experts, and leaders in biopharma, clinical services, diagnostics, genomics, precision medicine and laboratory testing services.
Slone Partners is a nationally recognized senior-level recruitment provider that specializes in delivering executive, management and leadership talent for the diagnostic, biopharmaceutical, healthcare information technology and laboratory testing industries. The firm has offices in Boston, New York, Washington, D.C. and San Francisco. Recently, the firm was included among Hunt Scanlon Media’s “Top 50 Healthcare & Life Sciences Search Firms.”
Slone Partners Recruits CEO for Mesa Biotech
The race is on to find a vaccine for COVID-19 – and along with it the pace is picking up to find top leadership talent at many of the nation’s leading life sciences, medical diagnostics and biotech companies. Here’s one of the latest searches just successfully completed.
Ms. Kochis-Stach joined Slone Partners in 2004, bringing to the company over a decade of healthcare experience. Her sales career with industry leaders such as VERSYSS, American Medical Laboratories and Quest Diagnostics covered a wide variety of healthcare segments, including information technology, medical records, and the diagnostic and laboratory testing industry.
The firm recently placed Mike Spigarelli as chief medical officer of Lumen Bioscience in Seattle, WA. “As an extremely skilled industry leader with three decades of medical, pharmaceutical and academic experience, Mike Spigarelli has a thorough understanding of clinical affairs, drug development and regulatory strategy,” said Ms. Kochis-Stach, of Slone Partners. “He will be a tremendously valuable addition to the Lumen Bio executive team at a time when the company is advancing a number of exciting new investigational biologic drugs.”
Related: Slone Partners Places Chief Medical Officer at Goldfinch Bio
Contributed by Scott A. Scanlon, Editor-in-Chief; Dale M. Zupsansky, Managing Editor; and Stephen Sawicki, Managing Editor – Hunt Scanlon Media